| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Nomegestrolacetate (0.3, 1, 3, 10, 30, 100 μM; 24, 48, and 72 hours) demonstrated dose-dependent antiproliferative action against RL95-2 cells [1]. In RL95-2 cells, nomegestrolacetate (4, 20, 100μM; 6, 24, 48h) increases the levels of the proteins Wnt7a and SUFU [1].
|
|---|---|
| ln Vivo |
Nomegestrol acetate slows the growth of RL95-2 xenograft tumors in vivo when taken orally once daily for 28 days at doses of 50, 100, or 200 mg/kg [1]. Nomegestrol acetate (oral; once daily for 28 days; 100–200 mg/kg) suppresses Wnt7a and SUFU expression in tumor tissues [1]. Rat ovulation is inhibited by nomegestrol acetate (1, 2.5 mg/rat); oral; once daily for 4 days [2].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: RL95-2 Cell Tested Concentrations: 0.3, 1, 3, 10, 30 and 100 µM Incubation Duration: 24, 48, 72 hrs (hours) Experimental Results: Inhibition of the growth of RL95-2 cells at a certain concentration In a sexual manner, the IC50 values at 48, 72 and 24 hrs (hours) were 19.88, 21.62 and 52.80 µM. Western Blot Analysis[1] Cell Types: RL95-2 Cell Tested Concentrations: 4, 20, 100 µM Incubation Duration: 6, 24, 48 hrs (hours) Experimental Results: Increased protein levels of SUFU and Wnt7a (relative to GAPDH expression) in a concentration-dependent manner Way. |
| Animal Protocol |
Animal/Disease Models: Female athymic nude mouse (BALB/c; 18-20g; 6 to 7 weeks old; xenograft nude mouse model) [1].
Doses: 50, 100, 200 mg/kg Route of Administration: po (oral gavage); one time/day for 28 days Experimental Results: diminished growth of RL95-2 xenograft tumors in vivo. The expression of SUFU and Wnt7a was upregulated in a dose-dependent manner at doses of 100 and 200 mg/kg. Animal/Disease Models: Mature female Wistar rats (approximately 200 grams) [2]. Doses: 1. 2.5 mg/rat. Route of Administration: po (po (oral gavage)) one time/day for 4 days. Experimental Results: Only one animal ovulated after receiving a dose of 1 mg/kg per day, and no animal ovulated after receiving 2.5 mg/rat per day. |
| References |
|
| Additional Infomation |
Nomegestrol acetate is a corticosteroid hormone.
Nomegestrol acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and for the treatment of gynecological disorders. |
| Molecular Formula |
C23H30O4
|
|---|---|
| Molecular Weight |
370.49
|
| Exact Mass |
370.214
|
| CAS # |
58652-20-3
|
| Related CAS # |
Nomegestrol;58691-88-6
|
| PubChem CID |
91668
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
507.3±50.0 °C at 760 mmHg
|
| Flash Point |
219.8±30.2 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
3.34
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
775
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@H]4C1=CC(=O)CC4
|
| InChi Key |
IIVBFTNIGYRNQY-YQLZSBIMSA-N
|
| InChi Code |
InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1
|
| Chemical Name |
[(8S,9S,10R,13S,14S,17R)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~168.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6991 mL | 13.4956 mL | 26.9913 mL | |
| 5 mM | 0.5398 mL | 2.6991 mL | 5.3983 mL | |
| 10 mM | 0.2699 mL | 1.3496 mL | 2.6991 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
